US2016220558A1PendingUtilityA1

Benzoquinoline inhibitors of vesicular monoamine transporter 2

Assignee: AUSPEX PHARMACEUTICALS INCPriority: Sep 18, 2008Filed: Apr 8, 2016Published: Aug 4, 2016
Est. expirySep 18, 2028(~2.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/16A61P 25/18A61P 25/00A61P 25/14A61P 1/16A61P 21/00A61K 31/4745C07B 59/00C07B 2200/05C07B 59/002A61K 45/06C07D 455/06
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 15 . (canceled) 
     
     
         16 . A method of treatment of a VMAT2-mediated disorder comprising the administration to a subject of a therapeutically effective amount of a compound having the structural formula 
       
         
           
           
               
               
           
         
       
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . The method as recited in  claim 16  further comprising the administration of an additional therapeutic agent. 
     
     
         20 . The method as recited in  claim 19  wherein said additional therapeutic agent is selected from the group consisting of olanzapine and pimozide. 
     
     
         21 . The method as recited in  claim 19  wherein said additional therapeutic agent is selected from the group consisting of benzodiazepines, and antipsychotics. 
     
     
         22 . The method as recited in  claim 21  wherein said benzodiazepine is selected from the group consisting of alprazolam, adinazolam, bromazepam, camazepam, clobazam, clonazepam, clotiazepam, cloxazolam, diazepam, ethyl loflazepate, estizolam, fludiazepam, flunitrazepam, halazepam, ketazolam, lorazepam, medazepam, dazolam, nitrazepam, nordazepam, oxazepam, potassium clorazepate, pinazepam, prazepam, tofisopam, triazolam, temazepam, and chlordiazepoxide. 
     
     
         23 . The method as recited in  claim 21  wherein said antipsychotic is selected from the group consisting of chlorpromazine, levomepromazine, promazine, acepromazine, triflupromazine, cyamemazine, chlorproethazine, dixyrazine, fluphenazine, perphenazine, prochlorperazine, thiopropazate, trifluoperazine, acetophenazine, thioproperazine, butaperazine, perazine, periciazine, thioridazine, mesoridazine, pipotiazine, haloperidol, trifluperidol, melperone, moperone, pipamperone, bromperidol, benperidol, droperidol, fluanisone, oxypertine, molindone, sertindole, ziprasidone, flupentixol, clopenthixol, chlorprothixene, thiothixene, zuclopenthixol, fluspirilene, pimozide, penfluridol, loxapine, clozapine, olanzapine, quetiapine, tetrabenazine, sulpiride, sultopride, tiapride, remoxipride, amisulpride, veralipride, levosulpiride, lithium, prothipendyl, risperidone, clotiapine, mosapramine, zotepine, pripiprazole, and paliperidone. 
     
     
         24 - 33 . (canceled)

Join the waitlist — get patent alerts

Track US2016220558A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.